Please login to the form below
Vaccibody name Martin Bonde as CEO
He joins from EpiTherapeutics where he holds the same role
Norwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.
Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma.
He joins from EpiTherapeutics, where he has held the role of CEO since 2009.
Tom Pike, chairman of Vaccibody, said: "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making.
“We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's' considerable potential”.
Bonde's experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- The Truth about Doctors
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
- The other side of … blood cancer
- To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
- COVID-19 – a catalyst for technology adoption in clinical trials
- As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Quick links
Infographics
